$274.06
0[0.00%]
At close: May 1
$274.06
0[0.00%]
After Hours: 4:00PM EDT
Bio-Rad Laboratories
(NYSE:BIO)Latest News for Bio-Rad Laboratories Stock (NYSE:BIO)
Bio-Rad Laboratories Stock (NYSE: BIO)
Categories: All
Tuesday, April 23, 2024
Monday, April 22, 2024
Thursday, April 18, 2024
Thursday, April 11, 2024
Wednesday, April 10, 2024
Wednesday, April 03, 2024
Wednesday, March 20, 2024
Friday, February 16, 2024
- Tech Stocks Ease On Hot PPI, Yields Rise, Microsoft, Amazon Snap 5-Week Positive Streak: What's Driving Markets Friday?Piero Cingari - Feb 16, 2024, 2:21PM
- Bio-Rad Laboratories shares are trading higher following Q4 earnings.Benzinga Newsdesk - Feb 16, 2024, 1:58PM
- RBC Capital Maintains Outperform on Bio-Rad Laboratories, Lowers Price Target to $480Benzinga Newsdesk - Feb 16, 2024, 12:16PM
- Applied Materials Posts Upbeat Earnings, Joins Texas Roadhouse, Vulcan Materials And Other Big Stocks Moving Higher On FridayAvi Kapoor - Feb 16, 2024, 10:09AM
Thursday, February 15, 2024
- Bio-Rad Laboratories: Q4 Earnings InsightsBenzinga Insights - Feb 15, 2024, 4:20PM
- Bio-Rad Laboratories Sees FY24 Non-GAAP Currency-Neutral Revenue Growth ~1.0%-2.5%; Non-GAAP Operating Margin ~13.5%-14.0%Benzinga Newsdesk - Feb 15, 2024, 4:18PM
- Bio-Rad Laboratories Q4 2023 Adj EPS $3.10 Beats $2.82 Estimate, Sales $681.20M Miss $685.09M EstimateBenzinga Newsdesk - Feb 15, 2024, 4:16PM
- Earnings Scheduled For February 15, 2024Benzinga Insights - Feb 15, 2024, 5:17AM
Wednesday, February 14, 2024
Friday, January 26, 2024
Tuesday, January 23, 2024
Thursday, December 07, 2023
Friday, November 24, 2023
Tuesday, November 14, 2023
Friday, October 27, 2023
Thursday, October 26, 2023
- 12 Health Care Stocks Moving In Thursday's After-Market SessionBenzinga Insights - Oct 26, 2023, 5:31PM
- Bio-Rad Currently Expects 2023 Non-GAAP Revenue To Decline By Approximately 3.5% On Currency-Neutral Basis Vs. Previous Estimate Of 0.8% Revenue GrowthBenzinga Newsdesk - Oct 26, 2023, 4:47PM
- Bio-Rad Laboratories Q3 Adj EPS $2.33 Misses $2.78 Estimate, Sales $632.12M Miss $689.57M EstimateBenzinga Newsdesk - Oct 26, 2023, 4:20PM
- Earnings Scheduled For October 26, 2023Benzinga Insights - Oct 26, 2023, 7:20AM
Wednesday, October 25, 2023
Tuesday, October 17, 2023
Monday, August 07, 2023
Friday, August 04, 2023
- Bio-Rad Laboratories shares are trading higher after the company reported better-than-expected Q2 EPS results and issued FY23 guidance. Additionally, RBC Capital raised its price target from $522 to $524 on the stock.Benzinga Newsdesk - Aug 4, 2023, 11:26AM
- RBC Capital Maintains Outperform on Bio-Rad Laboratories, Raises Price Target to $524Benzinga Newsdesk - Aug 4, 2023, 10:31AM
- The Latest Analyst Ratings for Bio-Rad LaboratoriesBenzinga Insights - Aug 4, 2023, 10:00AM
- Credit Suisse Maintains Outperform on Bio-Rad Laboratories, Lowers Price Target to $550Benzinga Newsdesk - Aug 4, 2023, 9:30AM
Thursday, August 03, 2023
- Excluding COVID-Related Sales, Bio-Rad Estimates FY23 Currency-Neutral Revenue Growth To Be About 4.5% (Prior 8.5%)Benzinga Newsdesk - Aug 3, 2023, 4:40PM
- Bio-Rad Currently Expects FY23 Non-GAAP Currency-Neutral Revenue Growth Of 0.8% (Previous Estimate Of 4.5%)Benzinga Newsdesk - Aug 3, 2023, 4:39PM
- Bio-Rad Laboratories Q2 Adj EPS $3.00 Beats $2.55 Estimate, Sales $681.10M Miss $687.88M EstimateBenzinga Newsdesk - Aug 3, 2023, 4:20PM
- Earnings Scheduled For August 3, 2023Benzinga Insights - Aug 3, 2023, 6:59AM
Wednesday, July 26, 2023
Friday, July 21, 2023
- Bio-Rad shares are trading higher after the company announced a $500 million share repurchase program. Also, Evelo Biosciences terminated its sublease agreement with the company and agreed to make a termination payment.Benzinga Newsdesk - Jul 21, 2023, 12:20PM
- Why Are Evelo Biosciences Stock Is Trading Higher Today?Vandana Singh - Jul 21, 2023, 9:48AM
Thursday, July 20, 2023
- Evelo Biosciences Terminated Their Sublease Agreement With Bio-Rad Laboratories, Agreeing To Make A Termination Payment Of $523,556 And Allowing Bio-Rad To Draw On A Letter Of Credit For $850,000 With The Potential For An Additional Payment Of Up To $2.5MBenzinga Newsdesk - Jul 20, 2023, 4:49PM
- Bio-Rad Plans New Share Repurchase Program For Up To $500M Shares Of Its Common StockBenzinga Newsdesk - Jul 20, 2023, 4:31PM
Friday, June 16, 2023
- The Latest Analyst Ratings for Bio-Rad LaboratoriesBenzinga Insights - Jun 16, 2023, 3:01PM
- Benzinga's Top Ratings Upgrades, Downgrades For June 16, 2023Benzinga Insights - Jun 16, 2023, 11:01AM
- Wells Fargo Initiates Coverage On Bio-Rad Laboratories with Overweight Rating, Announces Price Target of $550Benzinga Newsdesk - Jun 16, 2023, 5:46AM